Skip to main content
Clinical Trials/NCT06193096
NCT06193096CompletedNot Applicable

Evaluation of the Impact of a Probiotic-based Formula on Digestive Symptoms, General Symptoms and Mood in Ultra Runners

AB Biotics, SA2 sites in 1 country277 target enrollmentStarted: August 15, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
277
Locations
2
Primary Endpoint
Digestive symptoms associated to physical exercise

Study Overview

Brief Summary

Randomized, prospective, double-blind, placebo-controlled study in ultramarathon runners to evaluate the effects of suplementation with i3.1 probiotic formulation on the relief of common digestive symptoms associated to intense physical exercise. Secondary study outcomes aim to evaluate the effect of the probiotic formulation on fatigue, discomfort and muscle pain, as well as anxiety and mood.

Detailed Description

Gastrointestinal symptoms (GIS) are a common feature of intense exercise, especially in ultra-endurance events. The main objective of this study is to evaluate the impact of a 3-strain probiotic formulation comprising Lactiplantibacillus plantarum and Pediococcus acidilactici on digestive symptoms in a maximum of 300 runners registered in an organized ultra-marathon event. A randomized, prospective, double-blind, placebo-controlled study will be conducted. Once recruited, participants will be allocated to recieve either the probiotic or placebo (at a ratio 2:1) for 4 weeks prior to race day. During follow-up, study participants will fulfill several questionnaires at specific time points (baseline, week -3, -2, -1, -24 h previous to the race, as well as 24 h and 7 days after the race). This will be documented through a specifically designed, web-based platform. Digestive symptoms will be evaluated through validated questionnaires: modified from Pfeiffer et al (2012; main outcome) and the Gastrointestinal Symptoms Rating Scale (GSRS). Secondary objectives will comprise anxiety, mood, other symptoms (muscle pain, fatigue, respiratory symptoms), and performance in the ultra-marathon.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Age >18 years
  • Correctly registered in the Salomon Ultra Pirineu 100K® 2023 race
  • Stable medication planned during the study period
  • Willing to provide informed consent and follow study procedures
  • Have signed the consent provided by the organization of the Salomon Ultra Pirineu 100K® 2023 race

Exclusion Criteria

  • Respiratory, gastrointestinal or systemic infection that has caused fever or fatigue in the 15 days prior to the study entry
  • Having taken probiotic-based supplements or dairy products with probiotics (including "Actimel" or yogurts with "bifidus") daily in the 15 days prior to the study start
  • Taking oral or parenteral antibiotics in the 15 days prior to the study start
  • History of gastrointestinal surgery within 6 months prior to the study start
  • History of cardiovascular event: angina, heart failure, myocardial infarction
  • Diabetes mellitus type 1 or 2
  • Pregnancy or lactation, or women planning to conceive during the study period
  • Chronic gastrointestinal disease: inflammatory bowel disease (Crohn's disease, ulcerative colitis), pancreatitis, short bowel syndrome
  • Gastrointestinal disease or disorders: inflammatory bowel disease (ulcerative colitis, Crohn's disease), irritable bowel syndrome, chronic diarrhea or constipation
  • Diagnosis of severe kidney disease (chronic kidney failure) or liver disease (hepatitis, cholestasis, liver failure)

Outcomes

Primary Outcomes

Digestive symptoms associated to physical exercise

Time Frame: Baseline, +24 hours after race

Digestive tract digestive symptoms score measured with modified Pfeiffer questionnaire. Scoring ranges from 0 to 10 according to the intensity of the symptom (0-2 non-existent or mild symptoms; 3-7 moderate symptoms; 8-10 severe symptoms)

Secondary Outcomes

  • Race time(+24 hours after the race)
  • Competitive Anxiety before race(-24 hours (before race))
  • Digestive symptoms - subscore general digestive discomfort(Baseline, +24 hours after race)
  • Digestive symptoms - subscore other gastrointestinal symptoms(Baseline, +24 hours after race)
  • Digestive symptoms - subscore upper gastrointestinal symptoms(Baseline, +24 hours after race)
  • Digestive symptoms - subscore lower gastrointestinal symptoms(Baseline, +24 hours after race)
  • Digestive symptoms - percentage of severity(Baseline, +24 hours after race)
  • Digestive symptoms measured with GSRS(week -3, -2 and -1 previous race,-24 hours before race, +7 days after race)
  • Abandonment during the race(+24 hours after the race)
  • Adverse events(Baseline, week -3, -2, -1, -24 hours before race, +24 hours, +7 days after race)
  • Stool consistency(-24 hours before race, +24 hours after race)
  • Mood States(+24 hours, +7 days (after race))
  • Fatigue(-24 hours before race, +24 hours after race, +7 days)
  • Headache(-24 hours before race, +24 hours after race, +7 days)
  • Fever(Week -3, -2, -1, -24 hours before race, +24 hours, +7 days after race)
  • Muscle pain(-24 hours before race, +24 hours after race, +7 days)
  • Respiratory symptoms(Week -3, -2, -1, -24 hours before race, +24 hours, +7 days after race)
  • Sleep quality(Baseline, -24 hours before race, +7 days after race)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials